Research analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK stock opened at $0.44 on Friday. The company’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.90. The stock has a market capitalization of $3.70 million, a price-to-earnings ratio of -0.19 and a beta of 0.22. Evoke Pharma has a 1 year low of $0.42 and a 1 year high of $2.40.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The firm had revenue of $1.68 million for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- Golden Cross Stocks: Pattern, Examples and Charts
- Hasbro’s Management Made All the Right Calls This Quarter
- The Most Important Warren Buffett Stock for Investors: His Own
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Basic Materials Stocks Investing
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
